YY1 activates EMI2 and promotes the progression of cholangiocarcinoma through the PI3K/Akt signaling axis

Article Gastroenterology & Hepatology

A Circular RNA, Cholangiocarcinoma-Associated Circular RNA 1, Contributes to Cholangiocarcinoma Progression, Induces Angiogenesis, and Disrupts Vascular Endothelial Barriers

Yi Xu et al.

Summary: The study revealed that circ-CCAC1 is upregulated in cholangiocarcinoma (CCA) cells and extracellular vesicles (EVs), and plays a crucial role in promoting CCA tumorigenesis and metastasis through various mechanisms.

HEPATOLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

PCAT1 induced by transcription factor YY1 promotes cholangiocarcinoma proliferation, migration and invasion by sponging miR-216a-3p to up-regulate oncogene BCL3

Dongsheng Sun et al.

Summary: This study demonstrates that PCAT1 acts as an oncogene in cholangiocarcinoma (CCA) and is closely associated with disease progression. Overexpression of PCAT1 promotes malignant characteristics in tumors, while knockdown of PCAT1 inhibits these traits. Additionally, PCAT1 competitively binds miR-216a-3p to increase BCL3 expression and is regulated by the YY1 transcription factor.

BIOLOGICAL CHEMISTRY (2021)

Add to Collection

Article Cell Biology

Yin Yang 1-induced LINC00667 up-regulates pyruvate dehydrogenase kinase 1 to promote proliferation, migration and invasion of cholangiocarcinoma cells by sponging miR-200c-3p

Jinglin Li et al.

Summary: The study showed that LINC00667 is highly expressed in cholangiocarcinoma (CCA) and promotes CCA development by regulating the YY1/LINC00667/miR-200c-3p/PDK1 axis. Suppression of LINC00667 inhibits proliferation, migration, and invasion of CCA cells, suggesting a novel therapeutic strategy for CCA treatment.

HUMAN CELL (2021)

Add to Collection

Article Cell Biology

Circ-LAMP1 contributes to the growth and metastasis of cholangiocarcinoma via miR-556-5p and miR-567 mediated YY1 activation

Yi Xu et al.

Summary: The up-regulation of circ-LAMP1 in cholangiocarcinoma tissues and cell lines is associated with clinical severity, high post-operative recurrence, and poor prognosis. Circ-LAMP1 plays an oncogenic role in mediating cell growth, apoptosis, migration, and invasion, partially dependent on its modulation of YY1. This study suggests that circ-LAMP1 may serve as a promising biomarker/therapeutic target for cholangiocarcinoma.

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2021)

Add to Collection

Article Oncology

Intrahepatic Cholangiocarcinoma with Lymph Node Metastasis: Treatment-Related Outcomes and the Role of Tumor Genomics in Patient Selection

Joshua S. Jolissaint et al.

Summary: For node-negative patients, resection had the longest overall survival, while for node-positive patients, there was no difference in survival between resection and hepatic arterial infusion chemotherapy, both of which were superior to systemic chemotherapy alone. Patients with high-risk genetic alterations had poorer survival outcomes.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Oncology

Phase I-II Open-Label Multicenter Study of Palbociclib plus Vemurafenib in BRAFV600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism

Baptiste Louveau et al.

Summary: This study aimed to determine the potential clinical benefit of adding the CDK4 inhibitor Palbociclib to the treatment of patients with BRAF(V600E/KMUT) metastatic melanoma receiving Vemurafenib. Through clinical trials, it was found that the maximum tolerated dose of Palbociclib in treating these patients was 25mg, while also achieving some clinical responses.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Biochemistry & Molecular Biology

3-Arylamino-quinoxaline-2-carboxamides inhibit the PI3K/Akt/mTOR signaling pathways to activate P53 and induce apoptosis

Nan-Ying Chen et al.

Summary: The study synthesized thirty-eight new 3-arylaminoquinoxaline-2-carboxamide derivatives, with one compound (6be) showing the strongest anti-proliferative effect by inhibiting the PI3K-Akt-mTOR pathway to induce cell cycle arrest and apoptosis, while activating the P53 signaling pathway and modulating downstream target genes of Akt kinase. These compounds displayed moderate anti-tumor activity in vivo without showing obvious adverse reactions during drug administration, suggesting that 3-arylaminoquinoxaline-2-carboxamide derivatives could serve as a new scaffold for PI3K-Akt-mTOR inhibitors.

BIOORGANIC CHEMISTRY (2021)

Add to Collection

Review Oncology